Amyris, Inc. (AMRS) EPS Estimated At $-0.30

July 13, 2018 - By Mark Mitchell

Amyris, Inc. (NASDAQ:AMRS) Logo

Analysts expect Amyris, Inc. (NASDAQ:AMRS) to report $-0.30 EPS on August, 9.They anticipate $1.11 EPS change or 78.72 % from last quarter’s $-1.41 EPS. After having $-1.79 EPS previously, Amyris, Inc.’s analysts see -83.24 % EPS growth. The stock decreased 1.32% or $0.09 during the last trading session, reaching $6.71. About 276,806 shares traded. Amyris, Inc. (NASDAQ:AMRS) has risen 23.56% since July 14, 2017 and is uptrending. It has outperformed by 10.99% the S&P500.

Amyris, Inc. (NASDAQ:AMRS) Ratings Coverage

Among 3 analysts covering Amyris (NASDAQ:AMRS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amyris had 4 analyst reports since January 25, 2018 according to SRatingsIntel. B. Riley & Co maintained Amyris, Inc. (NASDAQ:AMRS) on Tuesday, March 20 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $1500 target in Monday, April 2 report. The rating was initiated by FBR Capital with “Buy” on Thursday, January 25. The stock has “Buy” rating by FBR Capital on Tuesday, May 29.

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company has market cap of $350.45 million. The firm uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It currently has negative earnings. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

More recent Amyris, Inc. (NASDAQ:AMRS) news were published by: Streetinsider.com which released: “Amyris (AMRS), BGI Agree to JV to Develop Products to Improve Human Health in Greater China” on June 26, 2018. Also Nasdaq.com published the news titled: “Amyris Expands Production Contract with ADL BioPharma Due to Demand Growth” on June 27, 2018. Nasdaq.com‘s news article titled: “Amyris Announces Non-Dilutive $36 Million Term Loan to Pay Off Stegodon and Other Short-Term Debt Maturities” with publication date: July 02, 2018 was also an interesting one.

Amyris, Inc. (NASDAQ:AMRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.